ReviewIntegrative cancer therapies2018
A Preclinical Evaluation of the Antitumor Activities of Edible and Medicinal Mushrooms: A Molecular Insight.
Review in Integrative cancer therapies, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 63 citations in OpenAlex.
- Modern Pro-Health Applications of Medicinal Mushrooms: Insights into theMolecules (Basel, Switzerland) · 2025Review
- Elucidating the mycochemistry and anticancer efficacy of F5 fraction of ethanolic extract of Daldinia eschscholtzii.Scientific reports · 2025Article
- Exploring the Anticancer Potential ofCurrent issues in molecular biology · 2025Review
- Harnessing the Nutritional Value, Therapeutic Applications, and Environmental Impact of Mushrooms.Food science & nutrition · 2025Review
- Mushroom-derived bioactive compounds pharmacological properties and cancer targeting: a holistic assessment.Discover oncology · 2025Review
- Current Advances in the Use of Mushrooms as Therapeutics for Lung Cancer: A Review.Molecules (Basel, Switzerland) · 2025Review
- Mycochemistry, antioxidant, anticancer activity, and molecular docking of compounds of F12 of ethyl acetate extract of Astraeus asiaticus with BcL2 and Caspase 3.Scientific reports · 2025Article
- The effect mechanism of ergosterol from the nutritional mushroomSaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024Article
- Anti-Cancer Potential of Edible/Medicinal Mushrooms in Breast Cancer.International journal of molecular sciences · 2023Review
- Therapeutic Effects of Medicinal Mushrooms on Gastric, Breast, and Colorectal Cancer: A Scoping Review.Cureus · 2023Article
- Bioactive Compounds from the Mushroom-Forming FungusAntibiotics (Basel, Switzerland) · 2023Article
- Current Uses of Mushrooms in Cancer Treatment and Their Anticancer Mechanisms.International journal of molecular sciences · 2022Review
- Mushroom Polysaccharide-Assisted Anticarcinogenic Mycotherapy: Reviewing Its Clinical Trials.Molecules (Basel, Switzerland) · 2022Review
- Therapeutic Potential of Hispidin-Fungal and Plant Polyketide.Journal of fungi (Basel, Switzerland) · 2021Review
- Article
- Latcripin-7A, derivative of Lentinula edodes CApplied microbiology and biotechnology · 2020Article
- Significance of Medicinal Mushrooms in Integrative Oncology: A Narrative Review.Frontiers in pharmacology · 2020Review
- A Review: The Bioactivities and Pharmacological Applications ofMolecules (Basel, Switzerland) · 2019Review
- LP1 fromInternational journal of molecular sciences · 2018Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is the leading cause of morbidity and mortality around the globe. For certain types of cancer, chemotherapy drugs have been extensively used for treatment. However, severe side effects and the development of resistance are the drawbacks of these agents. Therefore, development of new agents with no or minimal side effects is of utmost importance. In this regard, natural compounds are well recognized as drugs in several human ailments, including cancer. One class of fungi, "mushrooms," contains numerous compounds that exhibit interesting biological activities, including antitumor activity. Many researchers, including our own group, are focusing on the anticancer potential of different mushrooms and the underlying molecular mechanism behind their action. The aim of this review is to discuss PI3K/AKT, Wnt-CTNNB1, and NF-κB signaling pathways, the occurrence of genetic alterations in them, the association of these aberrations with different human cancers and how different nodes of these pathways are targeted by various substances of mushroom origin. We have given evidence to propose the therapeutic attributes and possible mode of molecular actions of various mushroom-originated compounds. However, anticancer effects were typically demonstrated in in vitro and in vivo models and very limited number of studies have been conducted in the human population. It is our belief that this review will help the research community in designing concrete preclinical and clinical studies to test the anticancer potential of mushroom-originated compounds on different cancers harboring particular genetic alteration(s).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.